Immunic
IMUX
68 hedge funds and large institutions have $114M invested in Immunic in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 12 reducing their positions, and 5 closing their positions.
293% more call options, than puts
Call options by funds: $763K | Put options by funds: $194K
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
158% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 12
13% more funds holding
Funds holding: 60 → 68 (+8)
0.57% more ownership
Funds ownership: 4.34% → 4.9% (+0.57%)
1% less capital invested
Capital invested by funds: $116M → $114M (-$1.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.15M |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$5.02M |
| 3 |
RI
RTW Investments
New York
|
+$4.43M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.84M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.25M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$575K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$373K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$146K |
| 5 |
Two Sigma Investments
New York
|
-$139K |
IMUX Hedge Fund Activity: Q3 2021 in Review
68 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q3 2021, worth a combined $114M — down 1.5% from $116M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IMUX positions and 5 closed out — a net gain of 8 holders — while 31 added to existing stakes and 12 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $6.15M. The largest seller was Fidelity Investments, cutting an estimated $1.25M.
- 68 institutional investors held Immunic (IMUX) as of Q3 2021, up from 60 in Q2 2021.
- Funds reported $114M of Immunic stock for Q3 2021, down 1.5% quarter-over-quarter.
- 13 funds opened new Immunic positions in Q3 2021 and 5 closed out, a net change of +8 holders.
- The largest Immunic buyer in Q3 2021 was Point72 Asset Management, an estimated $6.15M added.
- The largest Immunic seller in Q3 2021 was Fidelity Investments, an estimated $1.25M sold.
Based on aggregated 13F filings for Q3 2021.